1034842--3/2/2010--RIGEL_PHARMACEUTICALS

related topics

{product, candidate, development}

{product, liability, claim}

{stock, price, share}

{acquisition, growth, future}

{personnel, key, retain}

{tax, income, asset}

{financial, litigation, operation}

{condition, economic, financial}

{system, service, information}

{control, financial, internal}

{cost, regulation, environmental}

{operation, natural, condition}

{property, intellectual, protect}

{provision, law, control}

{cost, operation, labor}

{investment, property, distribution}

{stock, price, operating}

If our corporate collaborations or license agreements are unsuccessful, our research and development efforts could be delayed. If conflicts arise between our collaborators or advisors and us, any of them may act in their self-interest, which may be adverse to our stockholders' interests. If we are unable to obtain regulatory approval to market products in the United States and foreign jurisdictions, we will not be permitted to commercialize products from our research and development. We might not be able to commercialize our product candidates successfully if problems arise in the clinical testing and approval process. There is a high risk that drug discovery and development efforts might not successfully generate good product candidates. Our success is dependent on intellectual property rights held by us and third parties, and our interest in such rights is complex and uncertain. If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities and partnering. We will need additional capital in the future to sufficiently fund our operations and research. Our future funding requirements will depend on many uncertain factors. Our success as a company is uncertain due to our history of operating losses and the uncertainty of future profitability. Our ability to use net operating losses to offset future taxable income may be subject to certain limitations. Because we expect to be dependent upon collaborative and license agreements, we might not meet our strategic objectives. Delays in clinical testing could result in increased costs to us. We have been named a defendant in a purported securities class action lawsuit. This, and potential similar or related litigation, could result in substantial damages and may divert management's time and attention from our business. We lack the capability to manufacture compounds for development and rely on third parties to manufacture our product candidates, and we may be unable to obtain required material in a timely manner, at an acceptable cost or at a quality level required to receive regulatory approval. The restructuring of our research programs could result in management distractions, operational disruptions and other difficulties. If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated. Our ability to generate revenues will be diminished if our collaborative partners fail to obtain acceptable prices or an adequate level of reimbursement for products from third-party payors or government agencies. If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products. Our research and development efforts will be seriously jeopardized, if we are unable to attract and retain key employees and relationships. We depend on various scientific consultants and advisors for the success and continuation of our research and development efforts. If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages. Our facilities are located near known earthquake fault zones, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations. Future interest income and value of our investments may be impacted by further declines in interest rates and the broader effects of the recent turmoil in the global credit markets. Our stock price may be volatile, and our stockholders' investment in our stock could decline in value. Future equity issuances or a sale of a substantial number of shares of our common stock may cause the price of our common stock to decline. Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.

Full 10-K form ▸

1034842--3/2/2010--RIGEL_PHARMACEUTICALS_INC